Elevance Health Earnings: Stock Plunges 8.8% on Margin Compression

Why Did Elevance Health Earnings Trigger a Sell-Off?

In the second quarter of 2026, Elevance Health generated operating revenue of $49.8 billion, representing a modest year-over-year increase of 0.8%. This figure successfully cleared the consensus Wall Street estimate of $48.63 billion. On an adjusted basis, the company reported earnings per share (EPS) of $7.45, beating the analyst consensus estimate of $6.21. However, a deeper dive into the numbers reveals that this bottom-line performance was heavily supported by a net below-the-line benefit of approximately $0.80 per share. Without this one-time tailwind, the underlying operational decline would have been far more pronounced.

The primary catalyst for the stock’s decline was the visible pressure on profitability. The company’s overall operating margin contracted significantly, dropping to 3.5% from 4.9% in the prior-year period. The adjusted operating margin followed a similar downward trajectory, falling to 3.6% from 5.0%. This margin compression was particularly evident within the core Health Benefits division, where the operating margin shrank to 2.1% compared to 3.8% in the second quarter of 2025. Additionally, the benefit expense ratio rose by 80 basis points to 89.7%, driven by escalating medical costs within government-sponsored healthcare programs.

How Is the Health Benefits Segment Performing?

Despite the margin headwinds, Elevance Health experienced some positive momentum across its primary business units. The Health Benefits division generated total revenue of $42.7 billion, marking a 3% increase compared to the same period last year. This growth was primarily supported by higher premium yields and strong performance in the Individual Affordable Care Act (ACA) business, which helped offset headwinds in other areas. Meanwhile, the Carelon segment, which focuses on healthcare services and digital capabilities, reported a robust 6% revenue increase to $19.2 billion, driven by product revenue expansion at CarelonRx.

However, membership trends continue to pose a challenge for the insurer. Total medical membership stood at approximately 44.9 million at the end of June, representing a sequential decline of 469,000 members. Management attributed this contraction to the expected transition of a commercial fee-based customer, alongside anticipated declines in Medicaid and Individual ACA enrollment. This shrinking member base has intensified the pressure on the company to optimize its pricing strategies and manage medical costs more aggressively.

Will the 2026 Outlook Reassure Wall Street?

In response to the shifting operational environment, Chief Executive Officer Gail K. Boudreaux announced that the company is accelerating targeted investments. These strategic initiatives will focus on medical cost management, enhancing member experiences, improving provider connectivity, and scaling Carelon’s value-based solutions. Management believes these investments will solidify the company’s trajectory, paving the way for a return to at least 12% adjusted EPS growth in 2027 relative to the 2026 baseline.

Furthermore, the company raised its full-year guidance for fiscal year 2026. Elevance Health now expects GAAP EPS to reach at least $20.10, up from previous estimates, and lifted its full-year adjusted EPS guidance to at least $27.00, slightly above the consensus analyst estimate of $26.91. The company also upgraded its full-year operating cash flow forecast to at least $6.0 billion. Shareholders will also receive a third-quarter dividend of $1.72 per share, payable on September 25, 2026, to shareholders of record as of September 10, 2026.